Q3 2025 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2025-11-14 · accession 0001615982-25-000006
$1.78B
Reported value
33
Positions
2025-09-30
Period end
The Brief · Venrock Adviser, LLC · Q3 2025
AI · grounded in 13F
Venrock Adviser, LLC established a new position in APGE valued at $337.4M. The fund also initiated new stakes in METSERA INC for $196.3M and OCUL for $153.9M. Additional new positions include CDTX at $90.7M, VRDN at $83.8M, and KALV at $82M. Total AUM for the period stands at $1.78B across 33 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $337.4M | 19.0% | 8,493,321 | Common | SOLE |
| 59267L107 | — | METSERA INC | $196.3M | 11.0% | 3,750,662 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $153.9M | 8.66% | 13,161,462 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $90.7M | 5.10% | 946,788 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $83.8M | 4.72% | 3,882,709 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $82.0M | 4.61% | 6,728,985 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $79.8M | 4.49% | 4,148,428 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $79.2M | 4.46% | 6,596,885 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $66.0M | 3.72% | 3,226,331 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $57.4M | 3.23% | 4,000,000 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $49.6M | 2.79% | 15,561,500 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $49.0M | 2.76% | 576,729 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $45.3M | 2.55% | 12,681,043 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $45.0M | 2.53% | 2,685,448 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $38.9M | 2.19% | 17,857,083 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $37.8M | 2.13% | 960,803 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $34.5M | 1.94% | 5,046,414 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $31.9M | 1.80% | 1,230,769 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $27.8M | 1.56% | 3,220,364 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $27.5M | 1.55% | 2,173,913 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $24.4M | 1.37% | 499,966 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $22.0M | 1.24% | 1,169,298 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $20.1M | 1.13% | 4,631,216 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $17.9M | 1.01% | 2,457,348 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $16.8M | 0.95% | 674,599 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $16.5M | 0.93% | 1,387,864 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $11.5M | 0.65% | 610,808 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $8.2M | 0.46% | 1,379,965 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $8.2M | 0.46% | 632,931 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $8.0M | 0.45% | 750,000 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $4.6M | 0.26% | 1,609,569 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $3.3M | 0.19% | 437,708 | Common | SOLE |
| G1933S101 | CASIF | CASI PHARMACEUTICALS INC | $1.6M | 0.09% | 987,259 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.